Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile
2. Inc-424
3. Inc424
4. Inca24
5. Incb-018424
6. Incb-018424 Phosphate
7. Incb-018424 Salt
8. Incb-18424
9. Incb-18424 Phosphate
10. Incb018424
11. Incb018424 Phosphate
12. Jakafi
13. Jakavi
14. Opzelura
15. Ruxolitinib
16. Ruxolitinib (as Phosphate)
17. Ruxolitinib Monophosphate
1. 1092939-17-7
2. Jakafi
3. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Phosphate
4. Jakavi
5. Ruxolitinib (phosphate)
6. Ruxolitinib Monophosphate
7. Incb018424 Phosphate
8. Ruxolitinib (as Phosphate)
9. Incb-018424 Phosphate
10. Incb-018424 Salt
11. Ruxolitinib Phosphate [usan]
12. Incb-18424 Phosphate
13. Incb018424 Salt
14. Chebi:66917
15. 436lru32h5
16. 1092939-17-7 (phosphate)
17. (betar)-beta-cyclopentyl-4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazole-1-propanenitrile Phosphate
18. Incb-18424
19. Ruxolitinib Phosphate Salt
20. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile Phosphate
21. (3r)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Phosphate (1:1)
22. Phosphenoperoxoic Acid Compound With (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)- 1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile And Dihydrogen (1:1:1)
23. Opzelura
24. Unii-436lru32h5
25. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrilephosphoricacid
26. Jakafi (tn)
27. Jakavi (tn)
28. Ruxolitinib Phosphate(incb018424)
29. Inc 424 Phosphate
30. Incb 018424 Phosphate
31. Incb-424
32. Schembl1369365
33. Chembl1795071
34. Amy5620
35. Dtxsid00911086
36. Ruxolitinib Phosphate (jan/usan)
37. Ruxolitinib Phosphate [mi]
38. Ruxolitinib Phosphate [jan]
39. Ex-a2660
40. Cs1956
41. Mfcd18452860
42. S5243
43. Akos024464417
44. Ruxolitinib (incb-18424) Phosphate
45. Ruxolitinib Phosphate [who-dd]
46. Bcp9000783
47. Ccg-268687
48. Cs-0326
49. 1h-pyrazole-1-propanenitrile, Beta-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betar)-, Phosphate (1:1)
50. Ac-30901
51. As-74723
52. Hy-50858
53. Ruxolitinib Phosphate [orange Book]
54. Ruxolitinib (as Phosphate) [ema Epar]
55. D09960
56. J-501793
57. Q27135517
58. (3r)-3-cyclopentyl-3-(4-{7h-pyrrolo[2,3-d]pyrimidin-4-yl}-1h-pyrazol-1-yl)propanenitrile; Phosphoric Acid
59. (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric Acid
60. (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate
61. 1h-pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-,(.beta.r)-,phosphate (1:1)
62. Phosphoric Acid--3-cyclopentyl-3-[4-(1h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile (1/1)
| Molecular Weight | 404.4 g/mol |
|---|---|
| Molecular Formula | C17H21N6O4P |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 404.13619017 g/mol |
| Monoisotopic Mass | 404.13619017 g/mol |
| Topological Polar Surface Area | 161 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 503 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Jakafi |
| PubMed Health | Ruxolitinib (By mouth) |
| Drug Classes | Antineoplastic Agent |
| Active Ingredient | Ruxolitinib phosphate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base |
| Market Status | Prescription |
| Company | Incyte |
| 2 of 2 | |
|---|---|
| Drug Name | Jakafi |
| PubMed Health | Ruxolitinib (By mouth) |
| Drug Classes | Antineoplastic Agent |
| Active Ingredient | Ruxolitinib phosphate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 5mg base; eq 20mg base; eq 15mg base; eq 10mg base; eq 25mg base |
| Market Status | Prescription |
| Company | Incyte |
* Myelofibrosis (MF):
Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
* Polycythaemia vera (PV):
Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
* Graft versus host disease (GvHD):
Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5. 1).
Treatment of chronic Graft versus Host Disease (cGvHD)
Treatment of acute graft-versus-host disease (aGvHD)
Treatment of vitiligo
L01EJ01

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Iran
Brand Name : Relata
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Relata
Dosage Form : Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Relata
Dosage Form : Tablet
Dosage Strength : 15MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Relata
Dosage Form : Tablet
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : Ruxolitinib
Dosage Form : TABLET; ORAL
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number : 219660
Regulatory Info :
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : JAKAFI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Packaging :
Approval Date : 2011-11-16
Application Number : 202192
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : JAKAFI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Packaging :
Approval Date : 2011-11-16
Application Number : 202192
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : JAKAFI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 15MG BASE
Packaging :
Approval Date : 2011-11-16
Application Number : 202192
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : JAKAFI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 20MG BASE
Packaging :
Approval Date : 2011-11-16
Application Number : 202192
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : JAKAFI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 25MG BASE
Packaging :
Approval Date : 2011-11-16
Application Number : 202192
Regulatory Info : RX
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,339
2019 Revenue in Millions : 1,114
Growth (%) : 20

Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,595
2020 Revenue in Millions : 1,339
Growth (%) : 19

Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 1,561
2021 Revenue in Millions : 1,595
Growth (%) : -2

Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,720
2022 Revenue in Millions : 1,561
Growth (%) : 10

Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 1,936
2023 Revenue in Millions : 1,720
Growth (%) : 13

Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 71.20%
2013 Revenue in Millions :
Growth (%) :

Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 279
2014 Revenue in Millions : 410
Growth (%) : 47%

Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 581
2015 Revenue in Millions : 410
Growth (%) : 42

Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 777
2016 Revenue in Millions : 581
Growth (%) : 34

Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 977
2017 Revenue in Millions : 777
Growth (%) : 26%

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
23 Dec 2025
Reply
22 Apr 2025
Reply
24 Feb 2025
Reply
27 Aug 2024
Reply
24 Aug 2024
Reply
05 Aug 2024
Reply
12 Jul 2024
Reply
22 Jun 2024
Reply
02 Oct 2023
Reply
12 Jul 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Ruxolitinib Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ruxolitinib Phosphate manufacturer or Ruxolitinib Phosphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ruxolitinib Phosphate manufacturer or Ruxolitinib Phosphate supplier.
PharmaCompass also assists you with knowing the Ruxolitinib Phosphate API Price utilized in the formulation of products. Ruxolitinib Phosphate API Price is not always fixed or binding as the Ruxolitinib Phosphate Price is obtained through a variety of data sources. The Ruxolitinib Phosphate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Jakavi manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Jakavi, including repackagers and relabelers. The FDA regulates Jakavi manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Jakavi API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Jakavi manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Jakavi supplier is an individual or a company that provides Jakavi active pharmaceutical ingredient (API) or Jakavi finished formulations upon request. The Jakavi suppliers may include Jakavi API manufacturers, exporters, distributors and traders.
click here to find a list of Jakavi suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Jakavi DMF (Drug Master File) is a document detailing the whole manufacturing process of Jakavi active pharmaceutical ingredient (API) in detail. Different forms of Jakavi DMFs exist exist since differing nations have different regulations, such as Jakavi USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Jakavi DMF submitted to regulatory agencies in the US is known as a USDMF. Jakavi USDMF includes data on Jakavi's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Jakavi USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Jakavi suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Jakavi Drug Master File in Korea (Jakavi KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Jakavi. The MFDS reviews the Jakavi KDMF as part of the drug registration process and uses the information provided in the Jakavi KDMF to evaluate the safety and efficacy of the drug.
After submitting a Jakavi KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Jakavi API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Jakavi suppliers with KDMF on PharmaCompass.
A Jakavi written confirmation (Jakavi WC) is an official document issued by a regulatory agency to a Jakavi manufacturer, verifying that the manufacturing facility of a Jakavi active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Jakavi APIs or Jakavi finished pharmaceutical products to another nation, regulatory agencies frequently require a Jakavi WC (written confirmation) as part of the regulatory process.
click here to find a list of Jakavi suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Jakavi as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Jakavi API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Jakavi as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Jakavi and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Jakavi NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Jakavi suppliers with NDC on PharmaCompass.
Jakavi Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Jakavi GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Jakavi GMP manufacturer or Jakavi GMP API supplier for your needs.
A Jakavi CoA (Certificate of Analysis) is a formal document that attests to Jakavi's compliance with Jakavi specifications and serves as a tool for batch-level quality control.
Jakavi CoA mostly includes findings from lab analyses of a specific batch. For each Jakavi CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Jakavi may be tested according to a variety of international standards, such as European Pharmacopoeia (Jakavi EP), Jakavi JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Jakavi USP).